China a great AI med-tech market, but premarket review unpredictable | BioWorld
The three-step risk classification club stays small. NMPA and the FDA are two of the few regulatory agencies employing a three-tier risk ...
Read the original at BioWorld ↗
- Topics
- China & GeopoliticsRegulation & PolicyHealthcareGovernment & Public Sector
- Mentions
- ChinaFDA
- Tracked via
- “chinese ai threat”